2C-T-21
4-(2-fluoroethylthio)-2,5-dimethoxyphenethylamine
Viewing r1 — May 11, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
2C-T-21 (2,5-dimethoxy-4-(2-fluoroethylthio)phenethylamine) — also known as Aurora — is a synthetic psychedelic of the phenethylamine class. It is a close structural analog of 2C-T-2, with a longer duration and more empathogenic character. It activates serotonin receptors in the brain, disrupting normal filtering of sensory and emotional input to produce psychedelic effects.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, mescaline +4 moreLSD, psilocybin, mescaline, DMT, 2C-B, 2C-T-2, 2C-T-7 show less
Alexander Shulgin first synthesized 2C-T-21 and published the results in PiHKAL (1991).[1] It appeared on the research chemical market in the early 2000s but never gained the following of related compounds like 2C-B or 2C-T-7. It remains unscheduled in the United States but is controlled under class-wide phenethylamine laws in the United Kingdom, Canada, and Germany.
Subjective effects include tactile enhancement, mood elevation, social euphoria, increased communicativeness, and brightened colors. The experience is defined by empathogenic warmth — a sustained, gently stimulating sociability — rather than intense visuals or perceptual destabilization. Nausea during onset and anxiety at higher doses are common unsought effects.
2C-T-21 does not produce physical dependence, and no lethal dose has been established, though deaths have occurred within the broader 2C-T class.[2][3] The main danger is drug interactions — 2C-T-21 inhibits serotonin-clearing enzymes,[4] making combinations with antidepressants or monoamine oxidase-inhibiting plants potentially life-threatening. What is known comes from a single binding study,[5] limited self-reports, and structural analogy — the compound is poorly characterized.
History[edit]
Discovery
2C-T-21 was first synthesized by Alexander Shulgin during a systematic exploration of sulfur-substituted phenethylamines. It appears as Entry #49 in PiHKAL: A Chemical Love Story (1991),[1] with self-experimentation results placing the active oral dose at 8–12 mg and effects lasting 7–10 hours.[6] Shulgin described it as "about as potent a phenethylamine as they come."
Research and characterization
For decades after publication, 2C-T-21 remained pharmacologically uncharacterized beyond Shulgin's qualitative reports. Halberstadt et al. published the first receptor binding data in 2023, confirming potent serotonin receptor activity in animal models.[5] A separate study found that 2C-T-21 directly inhibits both MAO-A and MAO-B enzymes — a significant safety finding not anticipated from Shulgin's original reports.[4]
Market appearance and scheduling
2C-T-21 appeared on the research chemical market in the early 2000s alongside other Shulgin phenethylamines, but its user base remained small compared to 2C-T-2 or 2C-T-7. No specific incident prompted scheduling — control followed class-wide phenethylamine actions in the United Kingdom (2002), Canada (2016), and Germany (2016). In the United States, 2C-T-21 is not specifically scheduled, though the Federal Analogue Act is likely applicable.
The street name Aurora appears in community drug information sources, though its origin is unclear.[7] Myron Stolaroff characterized the compound as "not psychedelic, but a wonderful energizer" — an observation that positioned it as an outlier in the 2C-T series, leaning toward stimulant-empathogenic territory rather than classical psychedelia.[7]
Chemistry[edit]
Structural class
2C-T-21 belongs to the 2C-T-x series — a subgroup of phenethylamines built on a 2,5-dimethoxyphenethylamine scaffold with a sulfur-containing group at the 4-position. What distinguishes it from 2C-T-2 (which carries an ethylthio group) and 2C-T-7 (a propylthio chain) is a 2-fluoroethylthio group at C4. The terminal fluorine atom changes how the molecule interacts with metabolic enzymes, likely accounting for its distinct potency and duration profile.
Molecular identity
The molecular formula is C₁₂H₁₈FNO₂S (molecular weight 259.34 g/mol). No chirality centers are present — 2C-T-21 is achiral,[8] and the hydrochloride salt is commercially available as an analytical reference standard.[8] Physical property data — melting point, solubility, stability — have not been reported in the accessible literature.
Pharmacology[edit]
Mechanism of action
2C-T-21 produces psychedelic effects by activating serotonin receptors in the brain — the same pathway used by LSD, psilocybin, and mescaline.[5] Unlike MDMA, it does not release serotonin, dopamine, or norepinephrine[9] — it acts directly on the receptor rather than flooding the synapse.
A second significant action is direct inhibition of both MAO-A and MAO-B enzymes.[4] These enzymes break down serotonin, dopamine, and norepinephrine. Blocking them slows the clearance of those neurotransmitters — likely contributing to the stimulant-like energy and social warmth users describe, and creating dangerous interactions with other serotonergic drugs.
Pharmacokinetics
No human pharmacokinetic data exist for 2C-T-21. Based on related 2C-T compounds, monoamine oxidase enzymes are the primary pathway for clearing the compound,[10] with liver enzyme CYP2D6 contributing.inferred Because 2C-T-21 also inhibits those same MAO enzymes, it slows its own clearance — raising the risk that blood levels accumulate higher or last longer than expected.[10]
Neuroscience[edit]
Where it acts
As a potent serotonin receptor activator,[5] 2C-T-21 is expected to stimulate the same cortical nerve cells targeted by psilocybin and LSD — disrupting the brain's default filtering of perception and cognition to produce the characteristic psychedelic shift.
The monoamine oxidase inhibition adds a second layer[4]: by slowing the breakdown of serotonin, dopamine, and norepinephrine, 2C-T-21 may elevate monoamine levels in ways that account for the stimulant-like energy and social warmth users report.[7] This layering of receptor activation atop enzyme inhibition distinguishes the 2C-T class from tryptamine and lysergamide psychedelics.
Theoretical frameworks
The REBUS model proposes that serotonin receptor activation loosens the brain's high-level predictions, allowing sensory information to flow more freely. The gentle visual effects and prominent socioemotional character of 2C-T-21 may reflect a dose range that modestly relaxes these predictions without fully destabilizing perception. Whether 2C-T-21 promotes lasting structural brain changes — as some psychedelics may — has not been tested.
- Does the fluorine substitution alter how long 2C-T-21 occupies serotonin receptors compared to 2C-T-2, and does this explain reported differences in subjective character?
- What is the relative contribution of MAO inhibition versus serotonin receptor activation to the stimulant-empathogenic quality?
- Does 2C-T-21 promote brain changes comparable to psilocybin or other serotonin receptor agonists?
Subjective Effects[edit]
2C-T-21 sits at the empathogenic end of the psychedelic spectrum. The experience is defined by prosocial warmth and communicative fluency rather than visual intensity. Colors brighten and touch feels richer, but the dominant quality is a gently stimulating sociability — closer to energized emotional openness than the perceptual dissolution of classical psychedelics.
Relative to 2C-B, 2C-T-21 offers a longer, more emotionally engaged experience with less visual intensity.[7] Compared to 2C-T-7, it is gentler and more stimulant-leaning, with a narrower dose window. Both comparisons point to the same quality: this compound leans social, not visionary.
Effect Grid
Full empathogenic-psychedelic effects. Enhanced social bonding, aesthetic enhancement, and tactile euphoria define the experience. Communication flows freely; emotional enhancement and empathy enhancement are prominent. Mild visual effects appear — after-images, color enhancement, visual drifting — but remain secondary to the emotional-social character. Time alteration (dilation) is noticeable. Thought acceleration and novelty enhancement create a stimulant-tinged cognitive clarity.
Physically, stimulation and wakefulness are pronounced. Spontaneous body sensations and body high contribute warmth. Pupil dilation is consistent. Nausea is possible but generally mild. Shulgin reported a full "+3" experience at 12 mg with "excellent sleep" afterward.
This is the primary active range documented in PIHKAL (8–12 mg). The narrow window means precise dosing is critical — a 2 mg overshoot may push into strong territory. Duration is 7–12 hours depending on dose and individual metabolism.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Brightness alteration · Visual breathing · Touch enhancement · Auditory enhancement · Environmental patterning · Light sensitivity · Visual morphing · Tracers · Symmetrical texture repetition · After-images · Auditory distortion · Depth perception distortion · Perspective distortion · Sound sensitivity · Visual haze / noise · Proprioceptive distortion · Auditory misinterpretation · Peripheral misidentification · Peripheral vision distortion · Spatial disorientation · Visual acuity suppression · Visual diffraction · Visual melting · Synesthesia · Object transformations · Object activation · Visual recursion · Internal hallucinations · Environmental orbism / cubism · External hallucinations · Auditory hallucinations
Environmental patterning · Light sensitivity · Visual morphing · Tracers · Symmetrical texture repetition · After-images · Auditory distortion · Depth perception distortion · Perspective distortion · Sound sensitivity · Visual haze / noise · Proprioceptive distortion · Auditory misinterpretation · Peripheral misidentification · Peripheral vision distortion · Spatial disorientation · Visual acuity suppression · Visual diffraction · Visual melting · Synesthesia · Object transformations · Object activation · Visual recursion · Internal hallucinations · Environmental orbism / cubism · External hallucinations · Auditory hallucinations
Spontaneous body sensations · Stimulation · Muscle tension · Nausea · Wakefulness · Appetite suppression · Heart rate perception changes · Insomnia · Laughter fits · Physical fatigue · Restlessness · Tactile euphoria · Tingling / electric sensations · Vibrations / buzzing · Body schema distortion · Dizziness · Involuntary body movements · Bodily lightness · Bodily pressures · Breathing alteration · Dry mouth · Nystagmus (eye wobbles) · Sexual arousal enhancement · Temperature dysregulation · Excessive sweating · Watery eyes · Respiratory stimulation · Trembling · Dehydration sensation · Headache · Bruxism · Vomiting · Abnormal heartbeat · Diarrhea · Increased urination · Yawning · Bodily dissociation
Nausea · Wakefulness · Appetite suppression · Heart rate perception changes · Insomnia · Laughter fits · Physical fatigue · Restlessness · Tactile euphoria · Tingling / electric sensations · Vibrations / buzzing · Body schema distortion · Dizziness · Involuntary body movements · Bodily lightness · Bodily pressures · Breathing alteration · Dry mouth · Nystagmus (eye wobbles) · Sexual arousal enhancement · Excessive sweating · Watery eyes · Respiratory stimulation · Trembling · Dehydration sensation · Headache · Bruxism · Vomiting · Abnormal heartbeat · Diarrhea · Increased urination · Yawning · Bodily dissociation
Openness enhancement · Thought connectivity · Novelty enhancement · Conceptual thinking · Cognitive euphoria · Cognitive flexibility · Multiple thought streams · Immersion enhancement · Focus suppression · Thought acceleration · Creativity enhancement · Analysis enhancement · Cognitive fatigue · Cognitive impairment · Confusion · Humor enhancement · Information processing enhancement · Memory fragmentation · Synchronicity · Thought disorganization · Increased nature relatedness · Memory suppression · Thought loops · Language enhancement · Motivation enhancement · Information processing suppression · Focus enhancement · Cognitive dysphoria · Delusions
Conceptual thinking · Cognitive euphoria · Cognitive flexibility · Multiple thought streams · Immersion enhancement · Focus suppression · Thought acceleration · Creativity enhancement · Analysis enhancement · Cognitive fatigue · Cognitive impairment · Confusion · Humor enhancement · Information processing enhancement · Memory fragmentation · Synchronicity · Thought disorganization · Increased nature relatedness · Memory suppression · Thought loops · Language enhancement · Motivation enhancement · Information processing suppression · Focus enhancement · Cognitive dysphoria
Catharsis · Empathy enhancement · Anxiety · Dysphoria · Irritability
Irritability
Trust enhancement · Communication enhancement · Flow state · Sociability enhancement · Depersonalization · Boundary dissolution · Identity alteration · Cognitive disconnection · Ego dissolution
Depersonalization · Boundary dissolution · Identity alteration · Cognitive disconnection · Ego dissolution
Recursive awareness
Timeline
Slow, gradual emergence of awareness. Subtle mood shift, increased alertness, and faint sensory sharpening without overt psychedelic character.
Progressive build of stimulant and empathogenic effects. Sociability and talkativeness increase noticeably. Touch sensitivity and color richness begin.
Full empathogenic-psychedelic state. Enhanced communication, tactile euphoria, aesthetic enhancement, and mild visual effects. Stimulant energy sustains engagement.
Gradual reduction in psychedelic intensity. Stimulant residue and social warmth persist. Visual effects fade first; emotional openness lingers.
Residual mood elevation and slight introversion possible the following day. Sleep is generally not impaired at common doses — Shulgin reported 'excellent sleep. '
⚠ Avoid driving or operating heavy machinery for at least 12 hours after oral ingestion and until all residual effects have fully resolved.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
No lethal dose, therapeutic index, or controlled toxicology data exist for 2C-T-21. All toxicity assessments are class-level inferences, not substance-specific findings.inferred
Acute toxicity
No fatalities attributable specifically to 2C-T-21 have been published. This reflects the compound's low prevalence, not demonstrated safety.
Within the broader 2C series, at least five deaths have been documented, with excited delirium, rapid heart rate, elevated blood pressure, and dangerous overheating as characteristic features of severe intoxication.[3] One death from mono-intoxication with the structurally similar 2C-T-7 has been reported.[2]
Cardiovascular concerns
2C-T-21 partially activates a serotonin receptor subtype linked to heart valve damage with chronic exposure[11] — a risk established for other drugs like fenfluramine. No data confirm or rule out this risk for 2C-T-21.
Blood pressure and heart rate elevation are expected based on the pharmacology of related compounds.[12][13]
Neurotoxicity
Studies of related 2C-T compounds found concentration-dependent cell damage linked to mitochondrial dysfunction and oxidative stress.[14] These findings apply to 2C-T-21 by structural analogy; no substance-specific neurotoxicity data have been published.
Psychological risks
Community reports document an approximately 16–20% adverse psychological experience rate across 25 Erowid reports,[7] comparable to other serotonergic psychedelics in uncontrolled settings.
The narrow active dose range (8–12 mg)[6] amplifies psychological risk — an error of 2–3 mg above the intended dose can substantially escalate intensity. Standard psychedelic psychological risks apply: acute anxiety, panic, paranoia, psychotic episodes, and depersonalization that may persist beyond the acute phase.
Tolerance & dependence
Tolerance develops rapidly after a single dose, consistent with serotonin downregulation seen across all serotonergic psychedelics. Full baseline sensitivity returns within approximately 7 days. Cross-tolerance extends to other serotonin receptor agonists including LSD, psilocybin, mescaline, and other 2C compounds.citation needed
No evidence of physical dependence, withdrawal, or compulsive redosing has been reported. Dependence liability is consistent with the low abuse potential documented for serotonergic psychedelics as a class.
Drug interactions
The combination of serotonin receptor activation and direct monoamine oxidase inhibition gives 2C-T-21 an interaction risk profile exceeding that of non-MAO-inhibiting psychedelics.
Monoamine oxidase inhibitors — pharmaceutical (phenelzine, tranylcypromine, moclobemide) and botanical (harmaline, Banisteriopsis caapi, Syrian rue) — are the most dangerous combination. MAO enzymes are the primary clearance pathway for the 2C-T class,[10] and 2C-T-21's own MAO-inhibiting activity[4] adds further blockade — creating a trap in which the compound impairs the very enzymes needed to clear it. The result risks dangerous blood pressure spikes and serotonin overload.safety citation needed
Serotonergic medications (SSRIs, SNRIs, tricyclic antidepressants, triptans, tramadol) increase serotonin syndrome risk. Chronic SSRI use may also blunt psychedelic effects through serotonin receptor downregulation.[15]
Lithium produces synergistic serotonergic activity and lowers the seizure threshold — a combination associated with severe adverse events across serotonergic psychedelics.safety citation needed
Stimulants (amphetamines, cocaine) compound cardiovascular stress — elevated blood pressure, rapid heart rate, and abnormal heart rhythms.
Cannabis may intensify the psychedelic experience,[16] increasing the probability of overwhelming or difficult experiences.
Tramadol carries dual risk: serotonergic synergy and seizure threshold reduction.safety citation needed
Contraindications
The following contraindications are inferred from the pharmacological profile and class-level evidence. No substance-specific contraindication studies exist.inferred
Concurrent MAOI therapy is an absolute contraindication. 2C-T-21 depends on MAO enzymes for clearance[10] while simultaneously inhibiting those same enzymes[4] — a pharmacokinetic trap in which the drug cannot be cleared while it amplifies monoaminergic activity.
Personal or family history of psychotic disorders (schizophrenia, schizoaffective disorder, bipolar I with psychotic features) is an absolute contraindication, consistent with all serotonergic psychedelics.
Heart conditions (uncontrolled high blood pressure, coronary artery disease, irregular heart rhythms) are a relative contraindication given the expected cardiovascular effects and confirmed partial serotonin receptor activation.
Liver impairment is a relative contraindication — impaired liver function may substantially raise drug exposure because clearance involves MAO and CYP enzymes.safety citation needed
Concurrent serotonergic medication (SSRIs, SNRIs, TCAs, triptans, lithium) is a relative to absolute contraindication depending on the agent and dose, due to serotonin syndrome risk.
Pregnancy and lactation are absolute contraindications in the absence of reproductive toxicology data.safety citation needed
Seizure disorders are a relative contraindication, particularly in combination with other seizure-threshold-lowering substances.
Harm Reduction[edit]
Forms & Identification
2C-T-21 is a milligram-active powder that can be confused with dozens of other white or off-white 2C powders, several of which have significantly different dose ranges and risk profiles. The narrow active dose range makes accurate identification critical.
Quantitative testing through drug checking services provides the only reliable confirmation of identity and purity. Even among correctly identified samples, batch-to-batch concentration differences can meaningfully shift the effective dose within the compound's narrow window.
Guidelines
- Weigh every dose on a milligram-precision scale (0.001 g). The active range of 8–12 mg leaves no margin for estimation.
- Begin with a low dose and allow at least 90 minutes for full onset before considering redosing — the long duration means premature redosing compounds intensity for hours.
- Arrange for a sober companion, particularly at unfamiliar doses. The 7–12 hour duration demands planning for sustained support.
- Choose a comfortable, familiar environment. The experience's strong empathogenic character makes social settings natural, but maintain access to a quiet retreat space.
- Eat lightly 2–3 hours before — fasting may accelerate onset; a full stomach may delay it unpredictably.
- Clear the schedule for the full day. The extended duration and stimulant character can delay sleep well past the perceived end of effects.
Set & Setting
2C-T-21's empathogenic character makes it sensitive to social context. The experience amplifies the emotional tone of the environment — warm, trusted company enhances the prosocial effects, while tense or unfamiliar settings may channel the stimulant energy toward anxiety.
The 7–12 hour duration requires more environmental planning than shorter-acting psychedelics. Ensure access to comfortable seating, water, light snacks, and a quiet room for retreat. Outdoor settings work well during the peak but should include a sheltered fallback option.
Aftercare & integration. The extended duration — particularly the stimulant-like residual energy — can leave the body wired after the psychoactive effects have faded. Prioritize hydration, nutrition, and sleep in the 24 hours following the experience. Magnesium supplementation may ease residual muscle tension.
The empathogenic character can surface emotionally significant material. Journaling within the first 48 hours helps preserve insights before they fade. If the experience raised difficult emotions or memories, consider discussing them with a trusted friend or therapist familiar with psychedelic experiences.
Recovery & Support
2C-T-21 does not produce physical dependence, and compulsive use is rare among serotonergic psychedelics. If use becomes a pattern of avoidance — regularly using psychedelics to escape rather than explore — this warrants honest self-assessment.
Support resources include the Fireside Project (62-FIRESIDE / 623-473-7433), a psychedelic peer support line, and MAPS integration therapist directories for those seeking professional guidance after difficult experiences.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Uncomfortable anxiety or nausea during onset is common and not itself an emergency. Seek immediate help if any of the following occur: chest pain or pressure, seizure, loss of consciousness, severe confusion with inability to communicate, dangerous overheating (skin hot to touch, not sweating), or signs of self-harm.
Immediate steps:
- 1. Call emergency services if any emergency sign is present.
- 2. Move the person to a quiet, safe space.
- 3. Keep them cool — remove excess clothing, apply cool water if overheating.
- 4. Do not restrain unless there is immediate danger of self-harm or harm to others.
- 5. Stay with the person. Speak calmly and simply.
- 6. Do not induce vomiting.
What to tell the dispatcher: State the substance name (2C-T-21, a psychedelic phenethylamine), the approximate amount taken, when it was taken, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
2C-T-21 is not controlled under any United Nations scheduling convention. National-level control has followed class-wide phenethylamine scheduling actions rather than substance-specific proceedings.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled | Federal Analogue Act (21 U.S.C. § 813) likely applicable; structural similarity to Schedule I compounds 2C-T-2 and 2C-T-7 would support prosecution for sale or possession intended for human consumptioncitation needed |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled under phenethylamine catch-all clause, amended 2002citation needed |
| Canada | Schedule III (CDSA) | Effective October 31, 2016; possession, trafficking, and production offenses applycitation needed |
| Germany | Controlled (NpSG) | Neue-psychoaktive-Stoffe-Gesetz effective November 26, 2016; production, import, and distribution punishable; possession not punishable under NpSGcitation needed |
| Australia | Likely Schedule 9 (Prohibited Substance) | Not specifically confirmed for 2C-T-21; 2C-T-2 and 2C-T-7 are Schedule 9; class scheduling probable but requires TGA confirmationcitation needed |
Legal status changes frequently and varies by jurisdiction. This information reflects available data as of early 2026 and is not legal advice.
references
- [1]
- [2] ^abSchifano F, Deluca P, Agosti L, Martinotti G, Corkery JM, et al. (2005) New trends in the cyber and street market of recreational drugs? The case of 2C-T-7 ('Blue Mystic') — Journal of Psychopharmacology PMID:16272191
- [3] ^abDean BV, Stellpflug SJ, Burnett A, Engebretsen KM (2013) 2C or Not 2C: Phenethylamine Designer Drug Review — Journal of Medical Toxicology doi:10.1007/s13181-013-0295-x
- [4]
- [5] ^abcdHalberstadt AL, Luethi D, Hoener MC, Trachsel D, Brandt SD, Liechti ME (2023) Use of the head-twitch response to investigate the structure-activity relationships of 4-thio-substituted 2,5-dimethoxyphenylalkylamines — Psychopharmacology doi:10.1007/s00213-022-06279-2
- [6]